- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Endocrinology
Volume 2016 (2016), Article ID 9747863, 12 pages
Tetrahydro-iso-alpha Acids Antagonize Estrogen Receptor Alpha Activity in MCF-7 Breast Cancer Cells
1Institut Meurice, 1 avenue Emile Gryzon, 1070 Brussels, Belgium
2Yakima Chief-Hopunion LLC, 10 avenue A. Fleming, 1348 Louvain-La-Neuve, Belgium
3Commission Communautaire Française (Cocof), Service des Industries Biochimiques, Belgium
4Commission Communautaire Française (Cocof), Département des Substances Naturelles et de Biochimie, Belgium
Received 4 January 2016; Revised 18 March 2016; Accepted 29 March 2016
Academic Editor: Maria L. Dufau
Copyright © 2016 Maëlle Lempereur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tetrahydro-iso-alpha acids commonly called THIAA or Tetra are modified hop acids extracted from hop (Humulus lupulus L.) which are frequently used in brewing industry mainly in order to provide beer bitterness and foam stability. Interestingly, molecular structure of tetrahydro-iso-alpha acids is close to a new type of estrogen receptor alpha (ERα) antagonists aimed at disrupting the binding of coactivators containing an LxxLL motif (NR-box). In this work we show that THIAA decreases estradiol-stimulated proliferation of MCF-7 (ERα-positive breast cancer cells). Besides, we show that it inhibits ERα transcriptional activity. Interestingly, this extract fails to compete with estradiol for ERα binding and does not significantly impact the receptor turnover rate in MCF-7 cells, suggesting that it does not act like classical antiestrogens. Hence, we demonstrate that THIAA is able to antagonize ERα estradiol-induced recruitment of the LxxLL binding motif.
Estrogen receptor alpha (ERα) is a member of the nuclear receptor (NR) family known to act as ligand-dependent transcription factors. Involvement of ERα and its natural hormone (17β-estradiol; E2) in the growth of hormone-dependent breast cancer cells (around two-thirds of breast cancer cases) is established for a long time. Like other members of nuclear receptor family, ERα is characterized by five functional domains (i.e., A/B, C, D, E, and F domains). E2 binding, in the E-domain, induces several changes in ERα conformation leading to the transition of the receptor from an inactive to an active state. In this active state, ERα is known to activate the transcription of target genes through DNA binding (C-domain). However, this view should be fleshed out since E2-stimulated transcription appears to be a dynamic and multicomponent process [1–3]. Actually, this mechanism involves sequential recruitment and dissociations of a large number of coactivators and corepressors . These proteins play a major role, not only for the onset of the transcription but also in ERα behaviors such as translocation, turnover, and crosstalk with other signaling pathways. Hence, in a pharmacological point of view, search for compounds able to disturb ERα/coregulators interplay is an attractive approach to modulate the receptor activity (see  and references herein).
Today, two therapeutic strategies are proposed for the specific treatment of ERα-positive breast cancer. The first one is the direct inhibition of the receptor by using antiestrogens and the second one is the inhibition of E2 synthesis by means of aromatase inhibitors. Note that, directly or indirectly, these two strategies target, in fine, the hormone binding pocket of ERα located in its E-domain. Unfortunately, a proportion of patients are or can become resistant to these drugs [6–8]. Thus, compounds targeting a domain distinct from the ligand binding pocket may offer an alternative therapeutic strategy . In this respect, several compounds aimed at inhibiting coactivator recruitment (i.e., Coactivator Binding Inhibitors (CBIs)) have been developed [9–18]. The key element in this research was the discovery of a consensus sequence at the surface of NR coactivators: the LxxLL motif (L, leucine, and x, any other residue) also called NR-box [19–21]. This motif is found in several NR coactivators such as members of the CBP/p300 and SRC/p160 families. When ERα is activated by a ligand, conformational modifications induce the emergence of a hydrophobic groove (i.e., Activation Function-2 (AF-2)) in which leucines can be engulfed. By mimicking this sequence, peptidic and nonpeptidic CBIs are able to competitively inhibit the recruitment of ERα coactivators. It is worth noting that nonpeptidic CBIs are uniformly characterized by the presence of hydrophobic lateral chains that mimic leucines of the LxxLL motif [13, 22]. Triazines, pyrimidines, trithianes, cyclohexanes, or pyridyl-pyridines are different examples of scaffolds allowing a suitable orientation of these side chains.
Interestingly, structure of hop (Humulus lupulus L.) α-acids and their derivatives are close to nonpeptidic CBIs described here (Figure 1). α-acids are a family of structurally similar compounds extracted from the resin of mature hop strobili (see  for review). They are mostly used in brewing industry to provide beer bitterness. This family is mainly composed of three molecules, that is, humulone, cohumulone, and adhumulone. Actually, a thermal isomerization (acyloin-type ring contraction) of α-acids is required to reach the desired bitterness [24, 25]. This chemical process occurs during wort boiling, before cooling, and fermentation. It generates six compounds: cis- and trans-isohumulone, isocohumulone, and isoadhumulone. Because these compounds are light-sensitive and generate “stale off-flavor,” stable reduced isomerized α-acids are regularly used to avoid this drawback . Three kinds of reduced isomerized α-acids are commercially available; they are commonly called Rho, Tetra (hereunder called THIAA, Figure 1), and Hexa referring to the reduction of one, two, or three π-bounds, respectively.
In a pharmacological point of view, hop α-acids and their derivatives appear to be a promising class of molecules. First, these reduced isomerized α-acids molecules are known for their antibacterial properties . It has also been shown that they can restore insulin sensitivity in type II diabetes patients . Furthermore, these compounds are able to inhibit NF-κb, TNFα, mTOR, AP-1, and COX-2 [29–31]. Hence, it was shown that they exhibit anti-inflammatory and antiangiogenic properties and induce a proliferation inhibition in various cancer cell lines [32–39]. The present study highlights a new pharmacological property of hop α-acid derivatives, that is, THIAA, which impede ERα activity in MCF-7 breast cancer cells by a mechanism most probably depending on the recruitment inhibition of coactivators.
2. Materials and Methods
2.1. Hop Acids
Hop extracts used in this study are commercial preparations obtained from Yakima Chief-Hopunion LLC. Concerning tetrahydro-iso-alpha acids (THIAA), this extract was a clear aqueous solution of the potassium salts of hop-derived THIAA standardized at 9% w/w by HPLC. Before cell treatment, dilutions were made in analytical grade ethanol and percentages given in this work refer to dilutions of commercial preparations (v/v). Concentrations specified in all experiments represent dilutions of this stock solution. Hence, a 0.1% concentration corresponds to a solution of 90 mg/L, which, considering an average molecular weight of 365 g/mol, would represent a concentration of combined components of ca. 0.25 mM. Note that, for cell treatments, final ethanol concentrations do not exceed 0.1% v/v.
2.2. Cell Culture
MCF-7, MDA-MB-231, and MVLN cells were propagated at 37°C (5% CO2, humid atmosphere) in Earle’s based minimal essential medium (EMEM) supplemented with phenol red, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heat-inactivated fetal bovine serum (FBS) (all reagents from Invitrogen). This culture condition is referred to hereafter as “serum-complete culture condition". For steroid-free culture condition, experiments were performed in phenol red-free EMEM containing 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% charcoal-stripped FBS.
2.3. Proliferation Measurement: Crystal Violet Staining
Cells were seeded in 96-well plates (3000 cells/well). Twenty-four hours after seeding, cells were treated or not (control) for a period of 72 hours. Cell growth was then measured by crystal violet staining as previously described . Briefly, cells were washed with PBS, fixed for 15 minutes in glutaraldehyde (1% in PBS), and stained for 30 minutes with crystal violet (0.1% w/v in distilled water). After removal of dye excess, cell-bound crystal violet was extracted with 1% v/v Triton X-100 and absorbance was measured at 550 nm (Oasis UVM340 spectrophotometer).
2.4. Metabolic Activity Measurement: MTT Assay
Cells were seeded in 96-well plates (3000 cells/well). Twenty-four hours after seeding, cells were treated or not (control) for a period of 72 hours. Metabolic activity was then assayed by exposure to 0.03% MTT w/v. After medium removal, produced formazan was dissolved in DMSO (1 hour, room temperature, under agitation) for measurement by spectrophotometry at 550 (Oasis UVM340 spectrophotometer).
2.5. Apoptosis Measurement by Flow Cytometry: Annexin V-FITC/Propidium Iodine Labeling
Cells were seeded in 6-well plates (2.5 105 cells/well) and allowed to grow for 24 hours in serum-complete condition. Then, cells were treated or not (control) for a 24-hour period (serum-complete condition). After monolayer trypsinization, cells were labeled with annexin V-FITC and propidium iodine (Dead Cell Apoptosis, Invitrogen) according to manufacturer’s instructions. Cytometric analyses were carried out with an Attune acoustic focusing cytometer and data were analyzed using Attune cytometric software V2.1 (Applied Biosystems). Statistical analysis was performed by ANOVA followed by post hoc Tukey test (for values <0.05) using Fizz software.
2.6. Cell Cycle Measurement by Flow Cytometry
MCF-7 cells seeded in Petri dishes were treated during 72 hours with indicated compounds. After trypsinization and permeabilisation/fixation with 70% ethanol, cells were treated with DNase-free RNase (Invitrogen) and DNA was stained with propidium iodine (Invitrogen) at 10 μg/mL for 15 minutes. After a 2x dilution in PBS, cells were analyzed by flow cytometry. Cytometric analyses were carried out with an Attune acoustic focusing cytometer and data were analyzed using Attune cytometric software V2.1 (Applied Biosystems).
2.7. Clonogenicity Study
Cells were seeded in Petri dishes at low concentration (300 cells/well) in steroid-free culture condition. Twenty-four hours after seeding, cells were treated or not (control) with indicated compounds for a 72-hour period. Cells were then fixed and stained with crystal violet as described above. After staining, both number of colonies and number of cells per colony were counted. For the latter, data were subdivided into 4 classes (1-2, 3–6, 7–11, and more than 11 cells) according to a quartile calculation.
2.8. ERα-Dependent Transcription: Measurement by Luciferase Induction Assay
MVLN cells (MCF-7 stably transfected with pVit-tk-Luc reporter plasmid ) were seeded in 6-well plates in steroid-free culture condition and were treated for 24-hour with indicated compounds. Cells were then washed twice with PBS and luciferase activity was measured in cell lysates by luminometry using Luciferase Assay System (Promega) and a GenProbe Leader 50 luminometer. Results were normalized with respect to total protein content measured by BCA method (Pierce).
2.9. Western Blot Analyses
MCF-7 cells were seeded in Petri dishes in steroid-free culture condition. After 24 hours of treatment with indicated compounds cells were washed with PBS before lysis in RIPA buffer: TBS containing 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM NaF, 0.1 mM sodium orthovanadate, 0.6 mM PMSF, 0.3 mM TPCK, and protease/phosphatase inhibitor mix (Fisher Scientific). Lysates were clarified and protein concentration of each sample was determined by BCA assay (Pierce). After addition of LDS Sample 4x buffer (Invitrogen), samples were boiled for 5 minutes and submitted to electrophoresis on a 4–12% SDS-PAGE gel (Invitrogen). Separated proteins were electrotransferred onto Hybond ECL nitrocellulose membrane (GE Healthcare) using a semidry blotting apparatus (BioRad). Nonspecific sites were blocked with 5% nonfat dry milk in TBS containing 0.05% Tween 20 (2 hours, room temperature). Membranes were then incubated overnight at 4°C with primary antibodies (F-10 at 1/750 and MAB1501 at 1/3000 from Santa Cruz Biotechnology and Millipore, resp.). Detection was performed by chemiluminescence, using a peroxidase-coupled secondary antibody (1.5 hours, room temperature) and Western Pico Detection system (both from Pierce). Immunoblots were visualized using a ChemiDoc XRS+ camera and densitometric analyses were performed using ImageLab software (BioRad).
MCF-7 cells were seeded in 8-chamber Lab-Tek slides in steroid-free culture condition and allowed to grow for 24 hours before treatment with or without (control) indicated compounds. After 24 hours of incubation, monolayers were washed twice with PBS, fixed in a 3% paraformaldehyde-PBS solution (20 minutes, room temperature), and permeabilized with a 0.1% Triton X-100-PBS solution (5 minutes, room temperature, under agitation) and nonspecific binding sites were blocked with a 3% BSA-PBS solution (overnight, 4°C). Cells were then successively exposed to the primary antibody (F-10 at 1/100, Santa Cruz Biotechnology), a biotinylated secondary antibody (Pierce), and the DyLight 594-labeled streptavidin (Thermo Scientific). Estrogen receptor was then visualized by fluorescence microscopy (Nikon DXM1200C).
2.11. [3H]E2 Relative Binding Affinity Measurement in MCF-7 Cells
MCF-7 cells were seeded in 24-well plates in steroid-free culture condition and allowed to grow for 48 hours before analysis. After removal of the culture medium, cells were exposed during 40 minutes to radiolabeled E2 at 10−9 M (2, 4, 6, 7, 16, 17 3H(N)-estradiol from PerkinElmer) in the presence or absence of increasing concentrations of E2 or THIAA in serum-free and phenol red-free EMEM. Nonspecific binding was assessed by addition of a 1000-fold excess of unlabeled hormone. After labeling, cells were washed three times with PBS and cell-associated [3H]E2 was assessed by liquid scintillation counting (LS6500 scintillation counter, Beckman Coulter) after ethanol extraction.
2.12. Assessment of ERα-LxxLL Motif Association by TR-FRET
An in vitro Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assay was carried out to evaluate the association between a recombinant ERα containing a GST sequence and a fluorescein-labeled LxxLL peptide (ERα LanthaScreen, Life Technologies). This experiment was performed according to manufacturer’s instructions. Briefly, the receptor was incubated with or without indicated compounds for 30 minutes on ice. After adjunction of the terbium anti-GST antibody and the labeled peptide, samples were incubated during 1 hour and fluorescence was measured at 488 nm and 518 nm under a 332 nm excitation wavelength using a SpectraMax M5 fluorometer and data were analyzed using the SoftMax Pro software (Molecular Device).
2.13. Assessment of ERα-LxxLL Motif Association by ELISA
MCF-7 cells were seeded in Petri dishes in steroid-free culture condition and allowed to grow for 48 hours. Then, cells were treated or not (control) during 30 minutes with E2 at 10−9 M. Cells were washed twice with PBS and lysed with RIPA buffer. Samples (with or without THIAA or the LxxLL competitor peptide (AnaSpec) at indicated concentrations) were then submitted to an ELISA-based method in which the capture element is an LxxLL peptide (ERα Elisa NR peptide, Active Motif) according to manufacturer’s instructions. Binding of ERα to the plate was measured by colorimetry (measurement at 450 nm, Oasis UVM340 spectrophotometer), after addition of an anti-ERα primary antibody and of an HRP-conjugated secondary antibody.
3. Results and Discussion
3.1. Effect of THIAA on Proliferation and Metabolic Activity of Breast Cancer Cells
We have first selected a commercial preparation of α-acids, or derivatives, able to exhibit a significant effect on MCF-7 cells with a moderate influence on MDA-MB-231 cell line. These two breast cancer cell lines differ from each other by their hormone dependency. While the MCF-7 cells express a high level of ERα, the MDA-MB-231 cell line does not. Comparison of results obtained with these cell lines will provide first information about a potential effect on the estrogen receptor. Indeed, these compounds are known to exert cytotoxic actions on diverse cancer cells independently of ERα expression [37–39]. Results show that the preparation of tetrahydro-iso-alpha acids (hereafter called THIAA) exerts a higher effect on MCF-7 as compared to MDA-MB-231 cells toward their proliferation and their metabolic activity in serum-complete culture condition (Figure 2). Actually, in this condition (i.e., presence of steroids) THIAA at 0.01% (v/v) induces a proliferation decrease of 72% in MCF-7 versus 50% in MDA-MB-231 cells. Concerning the metabolic activity, for the same concentration, THIAA induces a decrease of 75% in MCF-7 and failed to affect MDA-MB-231 cells. In order to know how these data are relevant to a potential apoptosis induction, we studied the effect of THIAA on this physiological phenomenon by flow cytometry, for both cell lines (annexin V-FITC/propidium iodine labeling, Figure 3). Results show that, in serum-complete culture condition, THIAA mainly acts by increasing late apoptosis and necrosis (24 hours of treatment). Moreover, like for previous experiments, THIAA appears to be more efficient in MCF-7, as compared to MDA-MB-231 cells.
Hence, a specific effect of THIAA on the estrogen receptor would be conceivable. Therefore, we evaluated its effect on E2-stimulated MCF-7 proliferation (Figure 4, steroid-free culture medium). Interestingly, beside a general cytotoxic effect noticeable on both MDA-MB-231 and unstimulated MCF-7 cells, THIAA appears to exhibit an antiestrogenic effect. Indeed, THIAA completely abrogates the trophic effect of E2 on MCF-7 cells. Accordingly, cell cycle analyses by flow cytometry show that THIAA is able to reverse the effect of E2 on MCF-7 cell cycle progression (Figure 5). Complementary studies of clonogenicity were carried out in order to confirm these data (Figure 6). Results show that the effect of THIAA is mainly due to a slowdown of the cell cycle. Indeed, while its effect on the number of colonies appears weak, the size of colonies (number of cells/colony) is prominently affected when THIAA is used in cotreatment with E2. Of note, when compared to antiestrogens, that is, 4-OH-tamoxifen and fulvestrant at 10−6 M, THIAA at 0.01% appears more effective with regard to the growth arrest of E2-stimulated MCF-7 cells.
3.2. Effect of THIAA on ERα Transcriptional Activity
In the context of general (anti-)estrogenic properties, a link between MCF-7 proliferation and ERα transcriptional activity is established [3, 42–45]. In this study, experiments performed with MCF-7 cells stably transfected with a Vit-tk-Luciferase reporter gene (MVLN cells ; “Vit” refers to the promoter of the vitellogenin A2 of Xenopus laevis) exposed to THIAA revealed that the MCF-7 proliferation decrease described here is associated with a reduction of ERE-dependent transactivation (Figure 7). THIAA at 0.001% induces, in this regard, a decrease of both the basal (100% versus 32%) and the E2-induced (343% versus 123%) reporter gene activity. Note that, in the same conditions, THIAA failed to reduce Vit-tk-Luciferase reporter gene activity when transiently transfected in the ERα-negative Cos-7 cell line (data not shown), supporting the assumption that THIAA acts on ERα. In order to confirm these data, we assessed the expression of progesterone receptor (PgR), a standard ERα-regulated gene product. Western blot analyses of A and B isoforms of PgR (Figure 8) also show a decrease of ERα transcriptional activity even if THIAA efficiency appears lower as compared to the previous experiment. In fact, this decrease is noticeable in both basal (PgRB: 100% versus 39%; PgRA: 100% versus 79%) and E2-stimulated (PgRB: 405% versus 293%; PgRA: 1292% versus 887%) conditions.
3.3. Effect of THIAA on ERα Turnover and 3[H]E2 Binding Capacity
Classical antiestrogens, by inducing several ERα conformation changes, impact the receptor turnover rate. While partial antiestrogens, like tamoxifen, upregulate ERα, pure antiestrogens, like fulvestrant, induce its rapid proteasomal degradation. In order to evaluate whether the antagonistic properties of THIAA could be attributed to a classical mode of action, ERα protein level was assessed by both western blot and immunofluorescence (Figure 9). Results show that after 24 hours of treatment, THIAA does not significantly modulate ERα level suggesting that it does not act like conventional antiestrogens. Note that at higher concentrations and duration of treatment, THIAA slightly decreases ERα protein level (decrease of 31% after 48 hours of treatment with 0.01% THIAA, data not shown) suggesting that it may display an indirect effect on ERα turnover rate.
On the other hand, additional studies show that THIAA has no influence on E2-ERα association in MCF-7 cells (Figure 10). Indeed, conventional competitive assays indicate that THIAA, up to 0.1%, does not affect [3H]E2 binding, supporting the fact that it acts through a site distinct from the hormone binding pocket. Note that, even after 6 hours of incubation before binding assay, THIAA at 0.1% does not decrease MCF-7 [3H]E2 labeling (data not shown, ) reflecting its inaction regarding both ERα turnover rate and binding capacity.
3.4. Effect of THIAA on LxxLL Motif Recruitment
By contrast to classical antiestrogens, CBIs are molecules designed to impede the recruitment of LxxLL-containing coactivators on ERα (see  for review). To evaluate the potential CBI-like effect of THIAA, an in vitro TR-FRET system as well as an ex cellulo ELISA-based method were carried out (Figure 11). Note that, in both assays, THIAA failed to produce a significant effect in the absence of E2 (data not shown). In the first test that uses a purified recombinant ERα, THIAA decreases the ERα-E2/LxxLL binding like a competitor peptide containing this amino acid sequence (LxxLL peptide). This antagonistic effect appears obvious in the second test that uses E2-stimulated MCF-7 cell extracts (untreated cells were used for the control). In this case, treatment of cell extracts with THIAA completely abrogates the effect of E2, like the LxxLL competitor peptide. Hence, altogether, these results suggest that THIAA antagonizes the effect of E2 through a mechanism that depends on the coactivator binding pocket. In this regard and in view of the THIAA chemical structure, a direct competition with the LxxLL motif is proposed.
Investigation on natural compounds able to modulate cell signaling remains an attractive approach for the discovery of new drug candidates . Hop (Humulus lupulus L.) appears to be a reservoir of such bioactive compounds [47, 48]. Hence, a large number of works has been devoted to the study of hop-derived molecules. Nevertheless, in most cases, these studies highlight biological properties of polyphenols. In this work, we investigated biological effects of α-acids and their isomerized and subsequently reduced derivatives. These compounds are usually used in brewing industry to provide beer bitterness. Recently, several studies have shown that α-acids derivatives display interesting pharmacological properties. It was indeed shown that these compounds are able to regulate key signaling actors like NF-κb, TNFα, mTOR, AP-1, and COX-2 leading to interesting biological effects, like anti-inflammatory and antiangiogenic properties .
In this work we have shown that THIAA, an isomerized and reduced α-acid preparation, exhibits antiestrogenic properties. Indeed, when given to MCF-7 cells, THIAA abrogates cell proliferation increase induced by E2. This trophic effect inhibition is associated with an ERα transcriptional activity decrease. The fact that THIAA failed to significantly modulate ERα protein turnover and that it is unable to compete with [3H]E2 for ERα binding led us to assume that it does not act like classical antiestrogens through binding into the hormone binding pocket. In this view, THIAA general chemical structure seems to be not suitable for such an interaction. Regarding THIAA chemical structure (Figure 1), a competition with ERα coactivators seems more likely. ERα coactivator binding site is a hydrophobic groove delimited by residues of helices H3–H5 and H12 of the E-domain in which leucines of the LxxLL motif can be engulfed . One may consider that hydrophobic side chains of THIAA, by mimicking leucine residues, can interact with this binding site and, thereby, impede the recruitment of coactivators. This hypothesis is corroborated by in vitro and ex cellulo experimental data demonstrating that THIAA inhibits E2-induced ERα LxxLL motif recruitment.
Several compounds, called CBIs, have been synthesized to impede ERα/coactivators association. CBIs mainly act by producing a competitive inhibition in a site distinct from the ligand binding pocket. This approach is considered to be a valuable therapeutic strategy, especially when pharmacological ligands appear devoid of efficacy . In this view, a high proportion of patients is, or can become, resistant to conventional antihormone therapies. Hence, new therapeutic modalities are required to overcome ERα-positive breast tumors with de novo or acquired mechanisms of resistance. By highlighting a CBI-like effect of THIAA, this work could provide basis for the future development of new potent ERα antagonists. First-line approaches for the design and hemisynthesis of such compounds will be the identification of the α-acid derivative displaying the highest affinity for the LxxLL binding groove as well as docking methodologies.
The authors declare that they have no competing interests.
This study was supported by a grant from Meurice R&D (Crédit de Stimulation à la Recherche). The authors thank Marie-Hélène Dupuche and Dominique Vinette from Sopura SA for fluorescence microscopy analyses, Claire Lehoux for clonogenicity data analyses, Martine Roovers for [3H]E2 labeling experiments, and, finally, Anne-Catherine Vandeville for her kind linguistic help.
- D. M. Lonard and B. W. O'Malley, “The expanding cosmos of nuclear receptor coactivators,” Cell, vol. 125, no. 3, pp. 411–414, 2006.
- A. P. Dennis and B. W. O'Malley, “Rush hour at the promoter: how the ubiquitin-proteasome pathway polices the traffic flow of nuclear receptor-dependent transcription,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5, pp. 139–151, 2005.
- G. Leclercq, M. Lacroix, I. Laïos, and G. Laurent, “Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells,” Current Cancer Drug Targets, vol. 6, no. 1, pp. 39–64, 2006.
- R. Métivier, G. Reid, and F. Gannon, “Transcription in four dimensions: nuclear receptor-directed initiation of gene expression,” EMBO Reports, vol. 7, no. 2, pp. 161–167, 2006.
- G. Leclercq, D. Gallo, J. Cossy et al., “Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment,” Current Pharmaceutical Design, vol. 17, no. 25, pp. 2632–2653, 2011.
- S. Ali and R. C. Coombes, “Endocrine-responsive breast cancer and strategies for combating resistance,” Nature Reviews Cancer, vol. 2, no. 2, pp. 101–112, 2002.
- S. Mohla, V. Stearns, N. Sathyamoorthy, M. G. Rosenfeld, and P. Nelson, “The biology of hormone refractory breast and prostate cancer: an NCI workshop report,” Cancer Biology & Therapy, vol. 8, no. 21, pp. 1975–1985, 2009.
- B. Huang, M. Warner, and J.-Å. Gustafsson, “Estrogen receptors in breast carcinogenesis and endocrine therapy,” Molecular and Cellular Endocrinology, vol. 418, part 3, pp. 240–244, 2015.
- C.-Y. Chang, J. D. Norris, H. Grøn et al., “Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors α and β,” Molecular and Cellular Biology, vol. 19, no. 12, pp. 8226–8239, 1999.
- J. D. Norris, L. A. Paige, D. J. Christensen et al., “Peptide antagonists of the human estrogen receptor,” Science, vol. 285, no. 5428, pp. 744–746, 1999.
- A.-M. Leduc, J. O. Trent, J. L. Wittliff et al., “Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor—coactivator interactions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11273–11278, 2003.
- A. K. Galande, K. S. Bramlett, T. P. Burris, J. L. Wittliff, and A. F. Spatola, “Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions,” The Journal of Peptide Research, vol. 63, no. 3, pp. 297–302, 2004.
- A. L. Rodriguez, A. Tamrazi, M. L. Collins, and J. A. Katzenellenbogen, “Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor α coactivator binding,” Journal of Medicinal Chemistry, vol. 47, no. 3, pp. 600–611, 2004.
- D. Shao, T. J. Berrodin, E. Manas et al., “Identification of novel estrogen receptor α antagonists,” Journal of Steroid Biochemistry and Molecular Biology, vol. 88, no. 4-5, pp. 351–360, 2004.
- A. K. Galande, K. S. Bramlett, J. O. Trent, T. P. Burris, J. L. Wittliff, and A. F. Spatola, “Potent inhibitors of LXXLL-based protein-protein interactions,” ChemBioChem, vol. 6, no. 11, pp. 1991–1998, 2005.
- H.-B. Zhou, M. L. Collins, J. R. Gunther, J. S. Comninos, and J. A. Katzenellenbogen, “Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 15, pp. 4118–4122, 2007.
- J. R. Gunther, T. W. Moore, M. L. Collins, and J. A. Katzenellenbogen, “Amphipathic benzenes are designed inhibitors of the estrogen receptor α/steroid receptor coactivator interaction,” ACS Chemical Biology, vol. 3, no. 5, pp. 282–286, 2008.
- K. Tints, M. Prink, T. Neuman, and K. Palm, “LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 5680–5698, 2014.
- D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker, “A signature motif in transcriptional co-activators mediates binding to nuclear receptors,” Nature, vol. 387, no. 6634, pp. 733–736, 1997.
- P. M. A. Henttu, E. Kalkhoven, and M. G. Parker, “Af-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors,” Molecular and Cellular Biology, vol. 17, no. 4, pp. 1832–1839, 1997.
- A. Wärnmark, E. Treuter, J.-Å. Gustafsson, R. E. Hubbard, A. M. Brzozowski, and A. C. W. Pike, “Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor α,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21862–21868, 2002.
- J. Becerril and A. D. Hamilton, “Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides,” Angewandte Chemie—International Edition, vol. 46, no. 24, pp. 4471–4473, 2007.
- J. De Keukeleire, G. Ooms, A. Heyerick, I. Roldan-Ruiz, E. Van Bockstaele, and D. De Keukeleire, “Formation and accumulation of α-acids, β-acids, desmethylxanthohumol, and xanthohumol during flowering of hops (Humulus lupulus L.),” Journal of Agricultural and Food Chemistry, vol. 51, no. 15, pp. 4436–4441, 2003.
- I. Caballero, C. A. Blanco, and M. Porras, “Iso-α-acids, bitterness and loss of beer quality during storage,” Trends in Food Science and Technology, vol. 26, no. 1, pp. 21–30, 2012.
- M. G. Malowicki and T. H. Shellhammer, “Isomerization and degradation kinetics of hop (Humulus lupulus) acids in a model wort-boiling system,” Journal of Agricultural and Food Chemistry, vol. 53, no. 11, pp. 4434–4439, 2005.
- K. Huvaere, M. L. Andersen, L. H. Skibsted, A. Heyerick, and D. De Keukeleire, “Photooxidative degradation of beer bittering principles: a key step on the route to lightstruck flavor formation in beer,” Journal of Agricultural and Food Chemistry, vol. 53, no. 5, pp. 1489–1494, 2005.
- N. Yamaguchi, K. Satoh-Yamaguchi, and M. Ono, “In vitro evaluation of antibacterial, anticollagenase, and antioxidant activities of hop components (Humulus lupulus) addressing acne vulgaris,” Phytomedicine, vol. 16, no. 4, pp. 369–376, 2009.
- H. Yajima, E. Ikeshima, M. Shiraki et al., “Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor α and γ and reduce insulin resistance,” Journal of Biological Chemistry, vol. 279, no. 32, pp. 33456–33462, 2004.
- J.-C. Lee, J. K. Kundu, D.-M. Hwang, H.-K. Na, and Y.-J. Surh, “Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-κB and AP-1: IκB kinase and c-Jun-N-terminal kinase as respective potential upstream targets,” Carcinogenesis, vol. 28, no. 7, pp. 1491–1498, 2007.
- K. Yamamoto, J. Wang, S. Yamamoto, and H. Tobe, “Suppression of cyclooxygenase-2 gene transcription by humulon,” Advances in Experimental Medicine and Biology, vol. 507, pp. 73–77, 2002.
- K. Yamamoto, J. Wang, S. Yamamoto, and H. Tobe, “Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid,” FEBS Letters, vol. 465, no. 2-3, pp. 103–106, 2000.
- K. Yasukawa, M. Takeuchi, and M. Takido, “Humulon, a bitter in the hop, inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin,” Oncology, vol. 52, no. 2, pp. 156–158, 1995.
- J. Fuchimoto, T. Kojima, T. Okabayashi et al., “Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells,” Medical Molecular Morphology, vol. 46, no. 4, pp. 203–209, 2013.
- M. Shimamura, T. Hazato, H. Ashino et al., “Inhibition of angiogenesis by humulone, a bitter acid from beer hop,” Biochemical and Biophysical Research Communications, vol. 289, no. 1, pp. 220–224, 2001.
- A. J. Hall, J. G. Babish, G. K. Darland et al., “Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops,” Phytochemistry, vol. 69, no. 7, pp. 1534–1547, 2008.
- S. Hougee, J. Faber, A. Sanders et al., “Selective inhibition of COX-2 by a standardized CO2 extract of Humulus lupulus in vitro and its activity in a mouse model of zymosan-induced arthritis,” Planta Medica, vol. 72, no. 3, pp. 228–233, 2006.
- W.-J. Chen and J.-K. Lin, “Mechanisms of cancer chemoprevention by hop bitter acids (Beer Aroma) through induction of apoptosis mediated by fas and caspase cascades,” Journal of Agricultural and Food Chemistry, vol. 52, no. 1, pp. 55–64, 2004.
- M. Saugspier, C. Dorn, B. Czech, M. Gehrig, J. Heilmann, and C. Hellerbrand, “Hop bitter acids inhibit tumorigenicity of hepatocellular carcinoma cells in vitro,” Oncology Reports, vol. 28, no. 4, pp. 1423–1428, 2012.
- F. Cömert Önder, M. Ay, S. Aydoğan Türkoğlu, F. Tura Köçkar, and A. Çelik, “Antiproliferative activity of Humulus lupulus extracts on human hepatoma (Hep3B), colon (HT-29) cancer cells and proteases, tyrosinase, β-lactamase enzyme inhibition studies,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 31, no. 1, pp. 90–98, 2016.
- D. Gallo, F. Jacquemotte, A. Cleeren et al., “Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor α,” Molecular and Cellular Endocrinology, vol. 268, no. 1-2, pp. 37–49, 2007.
- M. Pons, D. Gagne, J. C. Nicolas, and M. Mehtali, “A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules,” BioTechniques, vol. 9, no. 4, pp. 450–459, 1990.
- D. M. Lonard, Z. Nawaz, C. L. Smith, and B. W. O'Malley, “The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation,” Molecular Cell, vol. 5, no. 6, pp. 939–948, 2000.
- G. Reid, M. R. Hübner, R. Métivier et al., “Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling,” Molecular Cell, vol. 11, no. 3, pp. 695–707, 2003.
- I. Laïos, F. Journé, D. Nonclercq et al., “Role of the proteasome in the regulation of estrogen receptor α turnover and function in MCF-7 breast carcinoma cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 94, no. 4, pp. 347–359, 2005.
- D. Gallo, I. Haddad, G. Laurent et al., “Regulatory function of the P295-T311 motif of the estrogen receptor alpha-does proteasomal degradation of the receptor induce emergence of peptides implicated in estrogenic responses?” Nuclear Receptor Signaling, vol. 6, article e007, 2008.
- A. G. Atanasov, B. Waltenberger, E.-M. Pferschy-Wenzig et al., “Discovery and resupply of pharmacologically active plant-derived natural products: a review,” Biotechnology Advances, vol. 33, no. 8, pp. 1582–1614, 2015.
- P. Zanoli and M. Zavatti, “Pharmacognostic and pharmacological profile of Humulus lupulus L.,” Journal of Ethnopharmacology, vol. 116, no. 3, pp. 383–396, 2008.
- L. R. Chadwick, G. F. Pauli, and N. R. Farnsworth, “The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties,” Phytomedicine, vol. 13, no. 1-2, pp. 119–131, 2006.
- M. Van Cleemput, K. Cattoor, K. De Bosscher, G. Haegeman, D. De Keukeleire, and A. Heyerick, “Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds,” Journal of Natural Products, vol. 72, no. 6, pp. 1220–1230, 2009.